Evommune is focused on discovering and developing novel therapies designed to treat and halt the progression of chronic inflammatory disease.

Evommune

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme

Evommune | 2,818 followers on LinkedIn. Inventing ways to treat inflammatory diseases, developing therapies that address symptoms and halt progressive disease. | Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.

Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease.

Evommune is different.

Emily Ip

Luis Peña

Research and Development Leader

Jeegar Patel, Ph.D.

Driven corporate development and strategy leader

Lauren Krusius

Thanks to Nasdaq for highlighting our Series C financing and to our mission to do something about chronic inflammation. #biotech #biotechnology #lifescience

Today, we announced the closing of a $115 million Series C financing co-led by new investors RA Capital Management and Sectoral Asset Management , with participation from additional new plus existing investors. We also welcomed Derek DiRocco , PhD and François Beaubien , Ph.D. to our Board of Directors. Proceeds will be used to support the advancement of our lead clinical programs in chronic urticaria and atopic dermatitis. Learn more: https://lnkd.in/gzjbRSUA #immunology #inflammation #urticaria #biotechnology

Thanks to New York Stock Exchange #NYSE for recognizing our $115 million Series C financing. #biotech #lifescience #biotechnology

Check out CURE article on Evommune's goal in developing new and improved treatment options for patients living with chronic inflammatory diseases. #inflammation #inflammatorydiseases #biotechnology https://lnkd.in/gNpdSaHG

Evommune wishes to congratulate Eli Lilly on obtaining FDA approval for Ebglyss™ (lebrikizumab-ibkz). Several of our current Evommune colleagues played a role in its development, and are proud of its approval. Our drive to continue to deliver meaningful new medicines to patients has never been stronger. Chronic inflammation destroys lives and Evommune is here to do something about it! https://lnkd.in/gzKkPXi7

All of us at Evommune are deeply saddened by the recent passing of Dr. Marcus Maurer, a scientific collaborator at the Institute of Allergology at Charité in Berlin. #dermatology #inflammation #immunology

Evommune will be presenting a corporate update, including this week’s news on the commencement of a Phase 2 trial in adult patients with chronic inducible urticaria, at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City. Presentation will take place on Thursday, September 5th at the Marriott Marquis.

Dermatology Times article on our Phase 2 trial in Chronic Inducible Urticaria. https://lnkd.in/gJHp65QE

Metric
Company Name	Evommune	ABIVAX Société Anonyme
Symbol		ABVX
MSH ID	COM:EVOMMUNE	COM:ABIVAX
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	FR
Stage
Employee Count		61
Website	evommune.com	abivax.com
LinkedIn	evommune	abivax
Founders

Metric
Market Cap		834.77M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

EVOM

COM:EVOMMUNE

Evommune

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue